GRAMPLUS ® Clofoctolo

GRAMPLUS ® is a Clofoctol based drug

THERAPEUTIC GROUP: Antibacterial for systemic use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications GRAMPLUS ® Clofoctolo

GRAMPLUS ® is indicated in the treatment of upper respiratory tract infections both acute and chronic and in the prophylaxis of post-operative infections in otorhinolaryngitis

Mechanism of action GRAMPLUS ® Clofoctol

GRAMPLUS ® is a drug based on Clofoctol, a synthetic antibiotic that is effective against infections caused by Gram positive microorganisms sensitive to the active ingredient and responsible for infections of the upper respiratory tract.

Administered rectally, it is rapidly absorbed by the mucosa, and through the circulatory stream reaches the lung and in particular the respiratory system where it performs its therapeutic action by altering the surface structures of the pathogenic element, in particular cell membrane and bacterial wall, making thus the microorganism particularly sensitive to osmotic lysis.

The most important therapeutic response was observed with regard to microorganisms such as Pneumococci, Staphylococci and Streptococci, which are responsible for clinical conditions, even serious ones at the level of the upper respiratory tract and the stomatological and otorhinolaryngological apparatus.

After completing its biological activity, and following a hepatic metabolism that includes important glucuronation reactions, Clofoctol is eliminated mainly via the bile.

Studies carried out and clinical efficacy

CLINICAL EFFECTIVENESS OF CLOFOCTOL IN THE TREATMENT OF RESPIRATORY DISEASES

Int J Clin Pharmacol Res. 1985; 5 (3): 175-9.

Clinical trial that demonstrates how the administration of Clofoctol through the rectum can determine a prompt regression of respiratory symptoms, adequately restoring the ventilatory capacities and at the same time offering an effective resolution also from the microbiological point of view.

BIO-DISTRIBUTION OF THE CLOFOCTOLO IN VIVO

J Antimicrob Chemother. 1987 May; 19 (5): 679-83.

A dated study that tests some pharmacokinetic characteristics of Clofoctol and in particular the ability to concentrate in the lung, in clinically significant quantities, following rectal administration.

All this would explain the high efficacy of this antibiotic against respiratory diseases.

PHARMACOKINETICS AND PHARMACODYNAMICS OF CLOFOCHTOL

J Chemother. 2012 Aug; 24 (4): 201-6. doi: 10.1179 / 1973947812Y.0000000018.

Interesting study that tests the pharmacokinetic and pharmacodynamic properties of Clofoctol, evaluating the potential drug resistance mechanisms developed by pathogens isolated from respiratory pathogenic findings.

Method of use and dosage

GRAMPLUS ®

Rectal suppositories of 100 mg - 200 mg - 750 mg of Clofoctol.

The GRAMPLUS ® based therapy should be defined by your doctor based on the patient's pathophysiological characteristics and the severity of his clinical picture.

Generally in adults, 5-day therapies are sufficient to guarantee a remission of the complained symptomatology.

Warnings GRAMPLUS ® Clofoctolo

The use of GRAMPLUS ® should be preceded by a careful medical examination in order to assess the prescriptive appropriateness and the possible presence of contraindications such as to limit its use.

It is recommended to handle the drug according to the appropriate instructions provided by the doctor and pharmacist, taking care to keep the drug out of the reach of children and from direct heat sources.

PREGNANCY AND BREASTFEEDING

Although the experimental studies present at the time do not present teratogenic effects on the fetus accidentally exposed to Cloftol during pregnancy, the absence of statistically significant clinical trials significantly limit the use of GRAMPLUS ® during pregnancy and in the subsequent period of breastfeeding

Interactions

Pharmacological interactions are not known at the moment that are of clinical concern.

Contraindications GRAMPLUS ® Clofoctolo

GRAMPLUS ® is contraindicated in patients who are hypersensitive to the active substance or to any of its excipients.

Undesirable effects - Side effects

The use of GRAMPLUS ® could lead to the appearance of clinically minor and fortunately transient side effects such as nausea, vomiting, diarrhea and abdominal cramps.

Rarely, hypersensitivity reactions to the drug have been observed such as rash, erythema, edema and in severe cases hypotension and anaphylactic shock.